MedTrace Logo

Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients

NCT01677897 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-03-05

No results posted yet for this study

Summary

The purpose of this study is to assess the impact of the addition of metformin to abiraterone on survival in patients with metastatic prostate cancer

Conditions

Interventions

DRUG

Metformin

Adding Metformin to Abiraterone in case of PSA-Progression

Sponsors & Collaborators

  • Janssen-Cilag Ltd.

    collaborator INDUSTRY

  • Kantonsspital Graubünden

    lead OTHER

Principal Investigators

  • michael mark, md · Kantonsspital Graubünden

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2017-12-31
Completion
2018-06-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01677897 on ClinicalTrials.gov